From: Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes
Parameters | Men | Women | Distribution | Data source | ||
---|---|---|---|---|---|---|
Detected | Undetected | Detected | Undetected | |||
Incidence | ||||||
 (100,000 person-years) | 658 |  | 666 |  | Fixed | Population estimates 23;24 |
HF Prevalence | ||||||
 NYHA I |  | 0.007 |  | 0.000 | Dirichlet | Cohort study [5] |
 NYHA II |  | 0.148 |  | 0.142 | Dirichlet | Cohort study [5] |
 NYHA III |  | 0.047 |  | 0.031 | Dirichlet | Cohort study [5] |
 NYHA IV |  | 0.000 |  | 0.000 | Dirichlet | Cohort study [5] |
Mortality (year) | 0.010 | Â | 0.007 | Â | Fixed | Population estimates [20] |
HF Mortality (year) | ||||||
 NYHA I | 0.042 | 0.043 | 0.035 | 0.036 | Fixed | Cohort estimate [5] |
 NYHA II | 0.066 | 0.067 | 0.056 | 0.057 | Fixed | Cohort estimate [5] |
 NYHA III | 0.103 | 0.105 | 0.087 | 0.089 | Fixed | Cohort estimate [5] |
 NYHA IV | 0.159 | 0.163 | 0.137 | 0.139 | Fixed | Cohort estimate [5] |
Annual HF costsa | ||||||
 NYHA I | €1777 | €1786 | €1172 | €1100 | Gamma | Cost study [38] |
 NYHA II | €2099 | €2114 | €1370 | €1302 | Gamma | Cost study [38] |
 NYHA III | €3235 | €3275 | €2070 | €2018 | Gamma | Cost study [38] |
 NYHA IV | €8752 | €8912 | €5470 | €5490 | Gamma | Cost study [38] |
Medication prescription | ||||||
 ACE-inhibitors | 0.53 | 0.53 | 0.27 | 0.18 |  | Cohort study [5] |
 Beta-blockers | 0.57 | 0.50 | 0.50 | 0.50 |  | Cohort study [5] |
Utilitiesb | ||||||
 Diabetes without diagnosed HF | 0.868 |  |  |  | Beta | Cohort study [5] |
 NYHA I | 0.855 | 0.817 |  |  | Beta | Cohort study [5] |
 NYHA II | 0.790 | 0.739 |  |  | Beta | Cohort study [5] |
 NYHA III | 0.734 | 0.685 |  |  | Beta | Cohort study [5] |
 NYHA IV | 0.665 | 0.683 |  |  | Beta | Cohort study [5] |